Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Rhona, Stein"'
Autor:
Chien-Hsing Chang, Yang Wang, Rhona Stein, Thomas M. Cardillo, David M. Goldenberg, Edmund A. Rossi
Supplementary Materials, Figures 1-7, Table 1 from Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d54d4e5446f3917841f58d99f7db1e9
https://doi.org/10.1158/0008-5472.22377108
https://doi.org/10.1158/0008-5472.22377108
Supplementary Table 1, Figures 1-5 from A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4463d40ad23401a0aab884f28fb2cdc1
https://doi.org/10.1158/0008-5472.22385132.v1
https://doi.org/10.1158/0008-5472.22385132.v1
The short circulating half-life and side effects of IFNα affect its dosing schedule and efficacy. Fusion of IFNα to a tumor-targeting monoclonal antibody (MAb-IFNα) can enhance potency due to increased tumor localization and improved pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a017d455037de1e3085d580fb9a73038
https://doi.org/10.1158/0008-5472.c.6501119
https://doi.org/10.1158/0008-5472.c.6501119
Publikováno v:
Oncotarget
TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bef1c6c9cf5be3c032a75d0fdd67a85
https://doi.org/10.18632/oncotarget.25615
https://doi.org/10.18632/oncotarget.25615
Autor:
Rhona Stein, Kenneth M. Rassnick, Margaret C. McEntee, David M. Goldenberg, Susan Chen, Cheryl E. Balkman, Rodney L. Page
Publikováno v:
Leukemia & Lymphoma. 52:273-284
A pilot study of anti-human leukocyte antigen (HLA)-DR monoclonal antibody (mAb) in dogs with lymphoma was undertaken to verify the suitability of a canine model to address therapeutically relevant endpoints prior to a full trial in dogs, and ultimat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60a28664bf8bc800dccdd54cdf57ee0c
https://doi.org/10.3109/10428194.2010.535182
https://doi.org/10.3109/10428194.2010.535182
Autor:
Richard R. Furman, Thomas M. Cardillo, Chien-Hsing Chang, Susan Chen, Xiaochuan Chen, Pankaj Gupta, Rhona Stein, David M. Goldenberg
Publikováno v:
Blood. 115:5180-5190
A humanized IgG4 anti–HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement activation, was examined for binding and cytotoxicity on leukemia, lymphoma, and multiple myeloma cell lines and chronic lympho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3080dc3a30f9d873ab5cc2231720e0e9
https://doi.org/10.1182/blood-2009-06-228288
https://doi.org/10.1182/blood-2009-06-228288
Publikováno v:
Blood. 113:6161-6171
The dock and lock (DNL) method is a new technology for generating multivalent antibodies. Here, we report in vitro and in vivo characterizations of 20-22 and 22-20, a pair of humanized hexavalent anti-CD20/22 bispecific antibodies (bsAbs) derived fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f70c1fc0f470ba53d45aeee8012504
https://doi.org/10.1182/blood-2008-10-187138
https://doi.org/10.1182/blood-2008-10-187138
Publikováno v:
Clinical Cancer Research. 15:2808-2817
Purpose: The humanized anti-CD74 monoclonal antibody, milatuzumab, is in clinical evaluation for the therapy of multiple myeloma (MM). The ability of milatuzumab to increase the efficacy of bortezomib, doxorubicin, and dexamethasone was examined in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::971d58c4a31279991a5b1dad17674e59
https://doi.org/10.1158/1078-0432.ccr-08-1953
https://doi.org/10.1158/1078-0432.ccr-08-1953
Autor:
Chien-Hsing Chang, Thomas M. Cardillo, David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Yang Wang
Publikováno v:
Cancer Research. 68:8384-8392
Multivalent antibodies, either monospecific or bispecific, may improve the efficacy of current therapeutic interventions involving a single monoclonal antibody (mAb). We have applied the Dock-and-Lock (DNL) method, a new platform technology for the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a8718816fb7776e0e09c0eb14ea3501
https://doi.org/10.1158/0008-5472.can-08-2033
https://doi.org/10.1158/0008-5472.can-08-2033
Autor:
Josette Carnahan, Hans J. Hansen, Alessandra Cesano, Zhengxing Qu, Kristen Hess, Rhona Stein, David M. Goldenberg
Publikováno v:
Molecular Immunology. 44:1331-1341
Epratuzumab is a humanized anti-CD22 monoclonal antibody currently in clinical trials for treatment of non-Hodgkin lymphoma (NHL) and certain autoimmune diseases. Here we report the results of investigations of epratuzumab's mode of action in compari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333c68e15b522e36551bc3746072ba7b
https://doi.org/10.1016/j.molimm.2006.05.007
https://doi.org/10.1016/j.molimm.2006.05.007